JP2013506715A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506715A5
JP2013506715A5 JP2012533248A JP2012533248A JP2013506715A5 JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5 JP 2012533248 A JP2012533248 A JP 2012533248A JP 2012533248 A JP2012533248 A JP 2012533248A JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5
Authority
JP
Japan
Prior art keywords
nitrogen
oxygen
membered
ring
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012533248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506715A (ja
JP6016635B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/051517 external-priority patent/WO2011044157A1/en
Publication of JP2013506715A publication Critical patent/JP2013506715A/ja
Publication of JP2013506715A5 publication Critical patent/JP2013506715A5/ja
Application granted granted Critical
Publication of JP6016635B2 publication Critical patent/JP6016635B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012533248A 2009-10-06 2010-10-05 Ｐｄｋ１インヒビターとして有用な複素環式化合物 Expired - Fee Related JP6016635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24909509P 2009-10-06 2009-10-06
US61/249,095 2009-10-06
PCT/US2010/051517 WO2011044157A1 (en) 2009-10-06 2010-10-05 Heterocyclic compounds useful as pdk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155272A Division JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Publications (3)

Publication Number Publication Date
JP2013506715A JP2013506715A (ja) 2013-02-28
JP2013506715A5 true JP2013506715A5 (enExample) 2013-11-14
JP6016635B2 JP6016635B2 (ja) 2016-10-26

Family

ID=43857093

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012533248A Expired - Fee Related JP6016635B2 (ja) 2009-10-06 2010-10-05 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Country Status (27)

Country Link
US (6) US9546165B2 (enExample)
EP (3) EP3466929B1 (enExample)
JP (5) JP6016635B2 (enExample)
KR (3) KR102097664B1 (enExample)
CN (1) CN102665718B (enExample)
AR (2) AR078540A1 (enExample)
AU (3) AU2010303567B2 (enExample)
BR (1) BR112012007747B8 (enExample)
CA (1) CA2776690C (enExample)
CY (1) CY1118143T1 (enExample)
DK (2) DK2485731T3 (enExample)
ES (2) ES2712875T3 (enExample)
HR (1) HRP20160967T1 (enExample)
HU (2) HUE028082T2 (enExample)
IL (4) IL295518B2 (enExample)
IN (1) IN2012DN03883A (enExample)
LT (1) LT2485731T (enExample)
MX (2) MX389288B (enExample)
PH (1) PH12012500674A1 (enExample)
PL (1) PL2485731T4 (enExample)
PT (1) PT2485731T (enExample)
RS (1) RS55101B1 (enExample)
RU (2) RU2615130C2 (enExample)
SI (1) SI2485731T1 (enExample)
SM (1) SMT201600275B (enExample)
TW (1) TWI525093B (enExample)
WO (1) WO2011044157A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
PL2485731T4 (pl) 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143423A2 (en) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2587232T3 (es) 2010-07-20 2016-10-21 Vestaron Corporation Triazinas y pirimidinas insecticidas
CA2810708A1 (en) 2010-09-16 2012-03-22 Hutchison Medipharma Limited Fused heteroaryls and their uses
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
CN103159741B (zh) * 2011-12-19 2016-08-24 天津市国际生物医药联合研究院 一类酪氨酸激酶抑制剂的制备和用途
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
CN102627632B (zh) * 2012-04-16 2014-06-18 中国科学院广州生物医药与健康研究院 一种胺基喹唑啉衍生物及其制备方法和用途
EA029892B1 (ru) 2012-04-25 2018-05-31 Такеда Фармасьютикал Компани Лимитед Азотсодержащее гетероциклическое соединение
HK1208154A1 (en) * 2012-05-08 2016-02-26 Anvyl, Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
KR20150135332A (ko) * 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6327483B2 (ja) * 2013-05-31 2018-05-23 日産化学工業株式会社 複素環アミド化合物
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC CONNECTION
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
RU2693484C1 (ru) 2013-11-22 2019-07-03 СиЭль БАЙОСАЕНСИЗ ЭлЭлСи Антагонисты гастрина для лечения и профилактики остеопороза
CN104130256B (zh) * 2014-08-01 2016-08-24 上海毕得医药科技有限公司 一种吡啶并[3,4-d]嘧啶-4（3H）-酮衍生物的制备方法
EP3209664B1 (en) * 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
KR101753654B1 (ko) 2015-10-21 2017-07-05 한국화학연구원 3-(4-(피페라진-1-일)벤즈아미도)-1h-피라졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
KR101753652B1 (ko) * 2015-10-21 2017-07-05 한국화학연구원 N-아릴-1h-피라졸로피리딘-3-아민 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
CN108697699A (zh) * 2015-10-23 2018-10-23 苏尼西斯制药有限公司 用于治疗癌症的杂环pdk1抑制剂
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
EP4063358B1 (en) 2016-12-22 2024-05-22 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2018164248A1 (ja) * 2017-03-10 2018-09-13 大塚化学株式会社 反応生成物及びゴム組成物
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.
WO2019094779A1 (en) * 2017-11-09 2019-05-16 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
CN109087534A (zh) * 2018-10-09 2018-12-25 王业宝 一种基于车辆行驶轨迹的交通冲突检测方法
KR102293339B1 (ko) * 2019-04-17 2021-08-25 이화여자대학교 산학협력단 아미노알코올을 포함하는 아민 화합물에 대한 형광 및/또는 원편광 이색성 센서용 신규 프로브 화합물, 및 이를 이용한 형광 및 원편광 이색성 동시 분석 방법
CN110066221B (zh) * 2019-05-16 2022-03-08 海门瑞一医药科技有限公司 一种环丙基甲胺的制备方法
WO2021064141A1 (en) * 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
KR102877132B1 (ko) * 2019-11-25 2025-10-27 주식회사 대웅제약 신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
EP4253383A4 (en) * 2020-12-31 2024-07-17 Tsinghua University PYRIDINE-2-AMINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE
AR127972A1 (es) * 2021-12-17 2024-03-13 Pi Industries Ltd Novedosos compuestos de piridina carboxamida bicíclica sustituida fusionada para combatir hongos fitopatogénicos
JP2025501141A (ja) * 2021-12-24 2025-01-17 サイロ プロプリエタリー リミテッド 化合物
WO2024040242A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
JP2026516206A (ja) * 2023-04-21 2026-05-20 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２デグレーダー及びその使用
CN117603068A (zh) * 2023-08-01 2024-02-27 常州寅盛药业有限公司 一种氨甲环酸的制备方法
WO2025076290A1 (en) * 2023-10-05 2025-04-10 Purdue Research Foundation 5-6-5/6-bisaryl compounds as flt3 inhibitors
CN117903069A (zh) * 2023-12-29 2024-04-19 苏州艾缇克药物化学有限公司 一种法匹拉韦中间体2-溴-5-氯吡嗪的合成方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175980A (en) * 1958-05-23 1965-03-30 Geigy Ag J R Compositions of matter of improved appearance in daylight, containing a 3.5-diaminopyrazine-2.6-dicarboxylic acid derivative
DE2143730A1 (de) * 1971-09-01 1973-03-08 Byk Gulden Lomberg Chem Fab Substituierte pyridine, verfahren zu deren herstellung und sie enthaltende arzneimittel
PL114780B1 (en) * 1978-03-10 1981-02-28 Inst Przemyslu Farmaceutic Process for preparing novel alkylamides of 2-anilinonicotinic acids
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP3258776B2 (ja) * 1993-06-30 2002-02-18 中外製薬株式会社 Ｎ−スチリルフェニルアミノ安息香酸誘導体
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP1140881B1 (en) 1998-12-23 2006-05-17 Eli Lilly And Company Antithrombotic amides
ATE240316T1 (de) * 1998-12-23 2003-05-15 Lilly Co Eli Heteroaromatische amide als inhibitoren von faktor xa
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003284217A1 (en) * 2002-10-16 2004-05-04 Smithkline Beecham Corporation Chemical compounds
AU2003286321A1 (en) * 2002-12-19 2004-07-14 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CA2531418A1 (en) * 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
MXPA06004438A (es) * 2003-10-24 2006-06-20 Schering Ag Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
AR049418A1 (es) * 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CA2610509A1 (en) 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US8435970B2 (en) * 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
WO2008016643A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008079294A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
MX2009010050A (es) * 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
US8367706B2 (en) * 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CA2764818A1 (en) * 2009-06-08 2010-12-16 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
PL2485731T4 (pl) 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1

Similar Documents

Publication Publication Date Title
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
Mokale et al. Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl) propanoic acid derivatives
AU2015355839B2 (en) Heterocyclic derivatives and use thereof
JP2015532295A5 (enExample)
JP2013503905A5 (enExample)
JP2016509047A5 (enExample)
JP2014503567A5 (enExample)
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
RU2010147404A (ru) Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы
US8822732B2 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
JP2009530424A5 (enExample)
KR20130099064A (ko) (아자)인돌리진 유도체 및 그 의약용도
JP2012504608A5 (enExample)
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2016525104A5 (enExample)
JP2024096821A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
KR101648377B1 (ko) 축합환 유도체 및 그 의약용도
JP2010510216A5 (enExample)
JPWO2005080322A1 (ja) フルオレン誘導体
JP2018538244A5 (enExample)
JP2017516824A5 (enExample)
JP5302214B2 (ja) Ｔｒｐｖ１受容体拮抗薬としてのｏ−置換ジベンジル尿素誘導体
KR102939670B1 (ko) Pdl1 체크포인트 억제제로서의 헤테로고리 면역조절제
JP7101359B2 (ja) Ｐｄ－ｌ１発現抑制作用を有する新規化合物